Oncolytics Biotech (ONCY) Revenue (2009 - 2020)

Oncolytics Biotech (ONCY) has reported Revenue for 7 consecutive years, with $26.7 million the latest figure, recorded in Q3 2020.

• On a quarterly basis, Revenue rose 117.18% year-over-year to $26.7 million in Q3 2020; TTM through Sep 2020 was $101.3 million, a 93.06% increase from a year earlier, with the FY2020 full-year figure at $31.2 million, changed N/A from the prior year.
• Revenue was $26.7 million for Q3 2020 at Oncolytics Biotech, down from $29.9 million in the prior quarter.
• Over five years, Revenue peaked at $30.6 million in Q1 2020 and troughed at $570027.0 in Q2 2017.
• A 5-year average of $15.6 million and a median of $14.1 million in 2019 frame the typical range for Revenue.
• Across the five-year window, Revenue slipped 24.15% in 2019 and surged 143.65% in 2020, its largest moves.
• Over 5 years, Revenue stood at $710374.0 in 2016, then slipped by 19.76% to $570027.0 in 2017, then jumped by 2303.39% to $13.7 million in 2018, then rose by 3.27% to $14.1 million in 2019, then surged by 88.8% to $26.7 million in 2020.
• The last three Revenue figures came in at $26.7 million (Q3 2020), $29.9 million (Q2 2020), and $30.6 million (Q1 2020), per Business Quant data.